Skip to main content
SpringerLink
Log in

The effect of indicators of CALLY index on survival in glioblastoma

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Introduction

Glioblastoma is the most common primary brain tumor in adults. Recently, research has been published on the potential prognostic indicators associated with different types of cancer. Due to the limited availability of data investigating the relationship between the CALLY index and glioblastoma patients, we aimed to conduct this study.

Materials and methods

Between January 2017 and December 2023, we conducted a study on patients diagnosed with glioblastoma. We collected demographic data and routine laboratory tests at the time of admission. To calculate the CALLY index, we used the formula (albumin value × lymphocyte count) / CRP value × 104. Parameters were compared for in-hospital mortality across different groups.

Results

The study analyzed 202 patients who met the inclusion criteria. Of these, 165 (81.7%) were classified as “survivors” and 37 (18.3%) as “deceased.” A comparison of hematologic parameters between the two groups showed a significantly lower CALLY index in the “deceased” group (3.05 (4.92)) compared to the “survivor” group (10.13 (13.69)) (p < 0.001). The study compared the parameters between groups with regard to in-hospital mortality.

Conclusions

Based on the results of the study, we conclude that the CALLY index can be considered an easily applicable indicator for the mortality of glioblastoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Mermut O, Inanc B (2020) The effect of indicators of systemic inflammatory response on survival in glioblastoma multiforme. Turk Neurosurg 30(5):658–665. https://doi.org/10.5137/1019-5149.JTN.27068-19.1

    Article  PubMed  Google Scholar 

  2. Bambury RM, Teo MY, Power DG et al (2013) The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol 114(1):149–154. https://doi.org/10.1007/s11060-013-1164-9

    Article  CAS  PubMed  Google Scholar 

  3. Jarmuzek P, Kozlowska K, Defort P et al (2023) Prognostic values of systemic inflammatory immunological markers in glioblastoma: a systematic review and meta-analysis. Cancers (Basel) 15(13):3339. https://doi.org/10.3390/cancers15133339

    Article  CAS  PubMed  Google Scholar 

  4. Tan AC, Ashley DM, López GY et al (2020) Management of glioblastoma: state of the art and future directions. CA Cancer J Clin 70(4):299–312. https://doi.org/10.3322/caac.21613

    Article  PubMed  Google Scholar 

  5. Weng W, Chen X, Gong S et al (2018) Preoperative neutrophil-lymphocyte ratio correlated with glioma grading and glioblastoma survival. Neurol Res 40(11):917–922. https://doi.org/10.1080/01616412.2018.1497271

    Article  CAS  PubMed  Google Scholar 

  6. Ji F, Fu S, Guo Z et al (2016) Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection. Oncotarget 7(44):72276–72289. https://doi.org/10.18632/oncotarget.10848

    Article  PubMed  PubMed Central  Google Scholar 

  7. Förnvik K, Maddahi A, Liljedahl E et al (2021) What is the role of CRP in glioblastoma? Cancer Treat Res Commun 26:100293. https://doi.org/10.1016/j.ctarc.2020.100293

    Article  PubMed  Google Scholar 

  8. Topkan E, Kucuk A, Ozdemir Y et al (2020) Systemic inflammation response index predicts survival outcomes in glioblastoma multiforme patients treated with standard Stupp protocol. J Immunol Res 2020:8628540. https://doi.org/10.1155/2020/8628540

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yang C, Hu BW, Tang F et al (2022) Prognostic value of Systemic Immune-Inflammation Index (SII) in patients with glioblastoma: a comprehensive study based on meta-analysis and retrospective single-center analysis. J Clin Med 11(24):7514. https://doi.org/10.3390/jcm11247514

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Chen N, Peng C, Li D (2022) Epigenetic underpinnings of inflammation: a key to unlock the tumor microenvironment in glioblastoma. Front Immunol 13:869307. https://doi.org/10.3389/fimmu.2022.869307

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Massara M, Persico P, Bonavita O et al (2017) Neutrophils in glioma. Front Immunol 8:1349. https://doi.org/10.3389/fimmu.2017.01349

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Zhou Y, Xiao D, Jiang X, Nie C (2023) EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma. J Transl Med 21(1):28. https://doi.org/10.1186/s12967-023-03883-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Chen J, Wang H, Deng C, Fei M (2023) SLC12A5 as a novel potential biomarker of glioblastoma multiforme. Mol Biol Rep 50(5):4285–4299. https://doi.org/10.1007/s11033-023-08371-y

    Article  CAS  PubMed  Google Scholar 

  14. Litak J, Mazurek M, Grochowski C et al (2019) PD-L1/PD-1 Axis in glioblastoma multiforme. Int J Mol Sci 20(21):5347. https://doi.org/10.3390/ijms20215347

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Yang M, Lin SQ, Liu XY et al (2023) Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: from the investigation on nutrition status and clinical outcome of common cancers study. Front Immunol 14:1131496. https://doi.org/10.3389/fimmu.2023.1131496

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lida H, Tani M, Komeda K et al (2022) Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinoma. HPB (Oxford) 24(1):101–115. https://doi.org/10.1016/j.hpb.2021.06.414

    Article  Google Scholar 

  17. Witthayanuwat S, Pesee M, Supaadirek C et al (2018) Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev 19(9):2613–2617. https://doi.org/10.22034/APJCP.2018.19.9.2613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Shi X, Li H, Xu Y et al (2022) The prognostic value of the preoperative inflammatory index on the survival of glioblastoma patients. Neurol Sci 43(9):5523–5531. https://doi.org/10.1007/s10072-022-06158-w

    Article  PubMed  PubMed Central  Google Scholar 

  19. Ha ET, Antonios JP, Soto H et al (2014) Chronic inflammation drives glioma growth: cellular and molecular factors responsible for an immunosuppressive microenvironment. Neuroimmunol Neuroinflammation 1(2):66–76

    Article  Google Scholar 

  20. Killock D (2020) Extent of resection is important across glioblastoma molecular subtypes. Nat Rev Clin Oncol 17(5):275. https://doi.org/10.1038/s41571-020-0344-8

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Health Science University Antalya Training and Research Hospital, Antalya, Turkey

    Umut Ogün Mutlucan & Cezmi Çağrı Türk

  2. Department of Emergency Medicine, Health Science University Antalya Training and Research Hospital, Muratpaşa, Antalya, Turkey

    Cihan Bedel, Fatih Selvi, Ökkeş Zortuk & Mustafa Korkut

Authors
  1. Umut Ogün Mutlucan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cihan Bedel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fatih Selvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ökkeş Zortuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cezmi Çağrı Türk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mustafa Korkut
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cihan Bedel.

Ethics declarations

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the Antalya Training and research hospital ethical committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mutlucan, U.O., Bedel, C., Selvi, F. et al. The effect of indicators of CALLY index on survival in glioblastoma. Ir J Med Sci (2024). https://doi.org/10.1007/s11845-024-03666-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11845-024-03666-w

Keywords

Search

Navigation